Long-term tolerability and serum concentration of bevacizumab (avastin) when injected in newborn rabbit eyes

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 7, 2010, Pages 3701-3708

  Wu, Wei Chi ^a,b   Lai, Chi Chun ^a,b   Chen, Kuan Jen ^a,b   Chen, Tun Lu ^a,b   Wang, Nan Kai ^a,b   Hwang, Yih Shiou ^a,b   Yeung, Ling ^a,b   Li, Lien Min ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; GLIAL FIBRILLARY ACIDIC PROTEIN; MONOCLONAL ANTIBODY; NEUROFILAMENT PROTEIN; OPSIN; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG MECHANISM; DRUG TOLERABILITY; ELECTRORETINOGRAM; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; NEWBORN; NONHUMAN; OPHTHALMOSCOPY; PRIORITY JOURNAL; RABBIT; ANIMAL; BIOAVAILABILITY; DRUG ANTAGONISM; DRUG EFFECT; ELECTRORETINOGRAPHY; FLUORESCENT ANTIBODY TECHNIQUE; INJECTION; METABOLISM; RETINA; ULTRASTRUCTURE; VITREOUS BODY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, MONOCLONAL; BIOLOGICAL AVAILABILITY; ELECTRORETINOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GLIAL FIBRILLARY ACIDIC PROTEIN; INJECTIONS; NEUROFILAMENT PROTEINS; OPSINS; RABBITS; RETINA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 77955896444     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4425     Document Type: Article

References (44)

1. Smith LE. Through the eyes of a child: understanding retinopathy through ROP. The Friedenwald Lecture. Invest Ophthalmol Vis Sci. 2008;49:5177-5182.
2. Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;1: 1024-1028.
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
4. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006;26:383-390.
5. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 2006;26:495-511.
6. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevaci-zumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology. 2006;113:2002-2012.
7. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113:1695-1705.
8. Mason JO III, Nixon PA, White MF. Intravitreal injection of bevaci-zumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol. 2006;142:685-688.
9. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006;26:275-278.
10. Jonas JB, Libondi T, von BS, Vossmerbaeumer U. Intravitreal bev-acizumab for vitreous haemorrhage. Acta Ophthalmol. 2008;86: 585-586.
11. Ruiz-Moreno JM, Montero JA, Lugo F, et al. Intravitreal bevaci-zumab in recurrent diabetic vitreous haemorrhage after vitrec-tomy. Acta Ophthalmol. 2008;86:231-232.
12. Chanana B, Azad RV, Patwardhan S. Role of intravitreal bevaci-zumab in the management of Eales' disease. Int Ophthalmol. 2010;30:57-61.
13. Iliev ME, Domig D, Wolf-Schnurrbursch U, et al. Intravitreal bev-acizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol. 2006;142:1054-1056.
14. Jaissle GB, Leitritz M, Gelisken F, et al. One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2009;247:27-33.
15. Prager F, Michels S, Kriechbaum K, et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol. 2009;93:452-456.
16. Kriechbaum K, Michels S, Prager F, et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol. 2008;92:518-522.
17. Spaide RF, Chang LK, Klancnik JM, et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol. 2009;147:298-306.
18. Kong L, Mintz-Hittner HA, Penland RL, et al. Intravitreous bevaci-zumab as anti-vascular endothelial growth factor therapy for reti-nopathy of prematurity: a morphologic study. Arch Ophthalmol. 2008;126:1161-1163.
19. Kusaka S, Shima C, Wada K, et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol. 2008;92:1450-1455.
20. Chung EJ, Kim JH, Ahn HS, Koh HJ. Combination of laser photo-coagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthal-mol. 2007;245:1727-1730.
21. Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez-Rojas ML, et al. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina. 2008;28:S19-S25.
22. Mintz-Hittner HA, Kuffel RR. Intravitreal injection of bevaci-zumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina. 2008;28:831-838.
23. Azad R, Chandra P. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol. 2007;55: 319; author reply 320.
24. Travassos A, Teixeira S, Ferreira P, et al. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging. 2007;38:233-237.
25. Rishi E, Rishi P, Ratra D, Bhende M. Off-label use of bevacizumab in retinopathy of prematurity. Retina. 2009;29:284-285.
26. Lalwani GA, Berrocal AM, Murray TG, et al. Off-label use of intra-vitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina. 2008;28:S13-S18.
27. Robinson GS, Ju M, Shih SC, et al. Nonvascular role for VEGF: VEGFR-1, -2 activity is critical for neural retinal development. FASEB J. 2001;15:1215-1217.
28. Gariano RF, Hu D, Helms J. Expression of angiogenesis-related genes during retinal development. Gene Expr Patterns. 2006;6: 187-192.
29. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina. 2006;26:257-261.
30. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114:855-859.
31. Lambrechts D, Carmeliet P. VEGF at the neurovascular interface: therapeutic implications for motor neuron disease. Biochim Bio-phys Acta. 2006;1762:1109-1121.
32. Kilic U, Kilic E, Jarve A, et al. Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways. J Neurosci. 2006;26:12439-12446.
33. Sopher BL, Thomas PS, LaFevre-Bernt MA, et al. Androgen receptor YAC transgenic mice recapitulate SBMA motor neu-ronopathy and implicate VEGF164 in the motor neuron degeneration. Neuron. 2004;41:687-699.
34. Kychenthal A, Dorta P, Katz X. Zone I retinopathy of prematurity: clinical characteristics and treatment outcomes. Retina. 2006;26: S11-S15.
35. Foroozan R, Connolly BP, Tasman WS. Outcomes after laser therapy for threshold retinopathy of prematurity. Ophthalmology. 2001;108:1644-1646.
36. O'Keefe M, Lanigan B, Long VW. Outcome of zone 1 retinopathy of prematurity. Acta Ophthalmol Scand. 2003;81:614-616.
37. Chan-Ling T, Stone J. Degeneration of astrocytes in feline retinop-athy of prematurity causes failure of the blood-retinal barrier. Invest Ophthalmol Vis Sci. 1992;33:2148-2159.
38. Inan UU, Avci B, Kusbeci T, et al. Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci. 2007;48:1773-1781.
39. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121:1684-1694.
40. Repka MX, Tung B, Good WV, et al. Outcome of eyes developing retinal detachment during the Early Treatment for Retinopathy of Prematurity Study (ETROP). Arch Ophthalmol. 2006;124:24-30.
41. Gilbert WS, Quinn GE, Dobson V, et al. Partial retinal detachment at 3 months after threshold retinopathy of prematurity: long-term structural and functional outcome. Multicenter Trial of Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Oph-thalmol. 1996;114:1085-1091.
42. Wu WC, Drenser KA, Lai M, et al. Plasmin enzyme-assisted vitrec-tomy for primary and reoperated eyes with stage 5 retinopathy of prematurity. Retina. 2008;28:S75-S80.
43. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391-400.
44. Yu L, Wu X, Cheng Z, et al. Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci. 2008; 49:522-527.